特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中枢神経系(CNS)バイオマーカーの世界市場

Central Nervous System Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 567964
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.17円で換算しております。
中枢神経系(CNS)バイオマーカーの世界市場 Central Nervous System Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、中枢神経系(CNS)バイオマーカーの世界市場について調査し、市場の概要、種類・用途・エンドユーザー・地域別の市場動向、市場促進・阻害要因および課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

  • 市場の定義
  • 調査手法

第2章 エグゼクティブサマリー

第3章 主な推論

第4章 市場概要

  • 市場概況
  • ファイブフォース分析

第5章 市場力学

  • 促進要因
  • 阻害要因
  • 市場機会
  • 市場課題

第6章 中枢神経系(CNS)バイオマーカーの種類

  • 安全性バイオマーカー
  • 薬効バイオマーカー
    • 薬力学マーカー
    • 効果予測バイオマーカー
    • 予後バイオマーカー
  • 検証バイオマーカー

第7章 中枢神経系(CNS)バイオマーカーの世界市場:セグメント別

  • 用途別
    • 創薬・開発
    • 個別化医療
    • 疾患リスク評価
    • その他
  • エンドユーザー別
    • 診断ラボ
    • 外来診療後
    • 病院
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南アフリカ

第8章 競合情勢

  • 合併・買収
  • 提携・協力・合意

第9章 企業プロファイル

  • Abastar Mdx, Inc.
  • Thermo Fisher Scientific
  • Abiant, Inc.
  • Merck & Co., Inc.
  • Diagenic Asa
  • Banyan Biomarkers
  • Avid Radiopharmaceuticals Inc.
  • Avacta Group Plc
  • その他

第10章 市場の将来展望

目次
Product Code: 47145

The global central nervous system biomarkers market is expected to register a CAGR of 12.5% over the forecast period. A biomarker is used to measure the biological state, presence of diseases and effects of treatments. With the advent of proteomics and genomics, the demand for central nervous system (CNS) biomarkers has increased. Due to rapid advancements in genomic technologies, genetics analyses have become essential in clinical practices and research. Moreover, with the advancement in technology, the CNS biomarker testing has become widely accessible and feasible, to perform even in small size laboratories. Certain CNS diseases are hereditary, which encouraged the search for common variant genes associated with nerve function and CNS disease phenotypes using genomic technologies. Furthermore, advanced imaging systems are aiding early diagnosis of various diseases, while reducing the mortality rate. Hence, the market studied is expected to witness steady growth over the forecast period, due to the development in proteomics, genomics, and imaging system.

Key Market Trends

Personalized Medicine Segment is Expected to Show Better Growth in the Forecast Years

Based on application, it is segmented into drug discovery & development, personalized medicine, and others. Precision medicine, also commonly referred to as personalized medicine, is one of the most promising approaches to tackle diseases. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing breakthrough products for the treatment of neurological disease. In addition, to support the advancement of precision medicine in chronic diseases, the former President of the United States, Barrack Obama announced the Precision Medicine Initiative (PMI) in 2015. The PMI was awarded USD 215 million investment in 2016, primarily aimed at accelerating biomedical research while providing clinicians with new tools and therapies for selecting biomarkers that will work best for individual patients. Hence, with the various government initiatives and wide applications of biomarkers in personalized medicine, the market is expected to grow better over the forecast period.

North America Dominates the Central Nervous System Biomarkers Market

The Central Nervous System Biomarkers market holds the largest share in the North America region. According to the American Cancer Society, approximately 1,735,350 new cancer cases were diagnosed in the United States in 2018 and there were around 609,640 deaths during the same year. The National Institute of Neurological Disorders and Stroke is mainly focusing on approaches that could facilitate the discovery and validation of robust biomarkers, primarily for better diagnosis and treatment of certain conditions. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Competitive Landscape

The global players in the central nervous system biomarkers market are - Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd., Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories, Inc., DiaGenic ASA, G-Biosciences, Merck KGaA and Thermo Fisher Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Development in Proteomics, Genomics and Imaging System
    • 4.2.2 Rising Investments from Government and Private Players
    • 4.2.3 Increasing Research and Development with Successful Clinical Trials of Biomarkers
  • 4.3 Market Restraints
    • 4.3.1 High Cost of CNS Biomarkers Tests and Diagnostics
    • 4.3.2 Reimbursement and Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of CNS Biomarkers
    • 5.1.1 Safety Biomarker
    • 5.1.2 Efficacy Biomarker
    • 5.1.3 Validation Biomarker
    • 5.1.4 Other
  • 5.2 By Application
    • 5.2.1 Drug Discovery & Development
    • 5.2.2 Personalized Medicine
    • 5.2.3 Others
  • 5.3 By End User
    • 5.3.1 Diagnostic Labs
    • 5.3.2 Clinics/Hospitals
    • 5.3.3 Research Centers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Acumen Pharmaceuticals Inc.
    • 6.1.2 Alseres Pharmaceuticals Inc.
    • 6.1.3 Aposense Ltd.
    • 6.1.4 Avacta Life Sciences Limited
    • 6.1.5 Banyan Biomarkers Inc.
    • 6.1.6 Bio-Rad Laboratories, Inc.
    • 6.1.7 DiaGenic ASA
    • 6.1.8 G-Biosciences
    • 6.1.9 Merck KGaA
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS